Selection and characterization of human respiratory syncytial virus escape mutants resistant to a polyclonal antiserum raised against the F protein

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Archives of Virology

• Publication date

  2012-03-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00705-012-1274-2PMID 22411099
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab.

  2012cited by this paper
• Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

  2011cited by this paper
• Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes

  2011cited by this paper
• Structural basis of respiratory syncytial virus neutralization by motavizumab

  2010cited by this paper
• Palivizumab-resistant human respiratory syncytial virus infection in infancy.

  2010cited by this paper
• Human respiratory syncytial virus and other viral infections in infants receiving palivizumab

  2008cited by this paper
• Functional Analysis of the Transmembrane Domain in Paramyxovirus F Protein-Mediated Membrane Fusion

  2008cited by this paper
• In Vitro and In Vivo Fitness of Respiratory Syncytial Virus Monoclonal Antibody Escape Mutants

  2006cited by this paper
• In Vivo Selection of Respiratory Syncytial Viruses Resistant to Palivizumab

  2005cited by this paper
• Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants.

  2004cited by this paper
• Mutations in Multiple Domains Activate Paramyxovirus F Protein-Induced Fusion

  2004cited by this paper
• Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats.

  2004cited by this paper
• A simplified plaque assay for respiratory syncytial virus--direct visualization of plaques without immunostaining.

  2004influential reference
• Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion

  2001cited by this paper
• N-Glycans of F Protein Differentially Affect Fusion Activity of Human Respiratory Syncytial Virus

  2001cited by this paper
• Molecular epidemiology of respiratory syncytial virus

  2001cited by this paper
• Molecular epidemiology of respiratory syncytial virus.

  2001cited by this paper
• Cleavage of the respiratory syncytial virus fusion protein is required for its surface expression: role of furin.

  2000cited by this paper
• Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden.

  1999cited by this paper
• BIOEDIT: A USER-FRIENDLY BIOLOGICAL SEQUENCE ALIGNMENT EDITOR AND ANALYSIS PROGRAM FOR WINDOWS 95/98/ NT

  1999cited by this paper
• Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture, and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter

  1999cited by this paper
• Mutations of respiratory syncytial virus attachment glycoprotein G associated with resistance to neutralization by primate polyclonal antibodies.

  1999cited by this paper
• Antigenic Structure of Human Respiratory Syncytial Virus Fusion Glycoprotein

  1998cited by this paper
• Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants.

  1997cited by this paper
• Respiratory syncytial virus: not just for kids.

  1997cited by this paper
• Response of foot-and-mouth disease virus C3 Resende to immunological pressure exerted in vitro by antiviral polyclonal sera.

  1995cited by this paper
• Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host.

  1995cited by this paper
• Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein.

  1993cited by this paper
• Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies.

  1992cited by this paper
• Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.

  1992cited by this paper
• Location of the epitope recognized by monoclonal antibody 63G on the primary structure of human respiratory syncytial virus G glycoprotein and the ability of synthetic peptides containing this epitope to induce neutralizing antibodies.

  1992cited by this paper
• Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus.

  1991cited by this paper
• The G protein of human respiratory syncytial virus: significance of carbohydrate side-chains and the C-terminal end to its antigenicity.

  1991cited by this paper
• Location of a highly conserved neutralizing epitope in the F glycoprotein of human respiratory syncytial virus

  1990cited by this paper
• Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function

  1989cited by this paper
• Modification of foot-and-mouth disease virus after serial passages in the presence of antiviral polyclonal sera.

  1989cited by this paper
• Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins

  1989cited by this paper
• Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.

  1988cited by this paper
• Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses.

  1988cited by this paper
• Respiratory Syncytial Virus

  1988cited by this paper
• Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice

  1987cited by this paper
• Respiratory syncytial virus fusion glycoprotein: further characterization of a major epitope involved in virus neutralization.

  1987cited by this paper
• Immunological differences between the envelope glycoproteins of two strains of human respiratory syncytial virus.

  1987cited by this paper
• Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity

  1987cited by this paper
• Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.

  1986cited by this paper
• Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein.

  1986cited by this paper
• Purification and characterization of the respiratory syncytial virus fusion protein.

  1985cited by this paper
• Monoclonal antibodies protect against respiratory syncytial virus infection in mice.

  1984cited by this paper
• Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein

  1983cited by this paper
• Respiratory syncytial virus polypeptides. III. The envelope-associated proteins.

  1983cited by this paper
• Two disulfide-linked polypeptide chains constitute the active F protein of paramyxoviruses.

  1977cited by this paper
• Respiratory syncytial virus infections

  1973cited by this paper
• Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex.

  1973cited by this paper
• Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection.

  1973cited by this paper

• A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein

  2019cites this paper
• Molecular characterization of the glycoprotein and fusion protein in human respiratory syncytial virus subgroup A: Emergence of ON-1 genotype in Iran.

  2019cites this paper
• Avaliação da susceptibilidade de mutantes de escape do vírus sincicial respiratório frente ao Palivizumab pelo método de microneutralização in vitro.

  2017cites this paper
• Antigenic Drift Defines a New D4 Subgenotype of Measles Virus

  2017cites this paper
• Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection

  2016cites this paper
• Functional study of protective immunity following DNA vaccination against viral haemorrhagic septicaemia in rainbow trout

  2016cites this paper
• Genetic variability in G2 and F2 region between biological clones of human respiratory syncytial virus with or without host immune selection pressure

  2015cites this paper
• Evolution of New Variants/Mutants of JE Virus, Its Effect on Neurovirulence, Antigenicity, Host Immune Responses and Disease Transmission in Endemic Areas

  2014cites this paper
• Influence of respiratory syncytial virus strain differences on pathogenesis and immunity.

  2013cites this paper